BriaCell Therapeutics (TSE:BCT) Shares Down 0.9% – What’s Next?

BriaCell Therapeutics Corp. (TSE:BCT)’s share price dropped 0.9% on Tuesday . The stock traded as low as C$5.42 and last traded at C$5.49. Approximately 2,415 shares traded hands during trading, a decline of 90% from the average daily volume of 25,077 shares. The stock had previously closed at C$5.54.

BriaCell Therapeutics Stock Performance

The firm has a 50 day simple moving average of C$5.65 and a two-hundred day simple moving average of C$9.32. The stock has a market cap of C$39.80 million, a P/E ratio of -0.38 and a beta of 1.95.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.